{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:21:38Z","timestamp":1788790898440,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cpcardiol.2026.103423","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:09:21Z","timestamp":1786547361000},"page":"103423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9531-8777","authenticated-orcid":false,"given":"Abdulhakim M.","family":"Alhazmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhr","family":"AlAyoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania E.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Albulushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2026.103423_bib0001","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0002","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0004","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: from mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0005","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0006","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0007","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jchf.2023.02.007","article-title":"The lure of cardiac metabolism in the diagnosis, prevention, and treatment of heart failure","volume":"11","author":"Rodolico","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0008","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0010","first-page":"1764","article-title":"Insights into the role of obesity in heart failure with preserved ejection fraction pathophysiology and management","volume":"41","author":"Hathorn","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0011","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0012","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0013","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103423_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jchf.2018.03.003","article-title":"Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction","volume":"6","author":"Reddy","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011366","article-title":"Uncovering unrecognized heart failure with preserved ejection fraction among individuals with obesity and dyspnea","volume":"17","author":"Kosyakovsky","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0019","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"The role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-025-02612-z","article-title":"Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity","volume":"24","author":"van Dalen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0018","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvx107","article-title":"Ventricular-arterial coupling in heart failure with preserved ejection fraction: the devil is in the details","volume":"113","author":"Fraser","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0021","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103423_bib0022","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-preserved trial: principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0023","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0024","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0025","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0026","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103423_bib0027","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0028","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0029","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0031","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103423_bib0032","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0033","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0034","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103423_bib0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0041","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0042","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0036","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)","volume":"402","author":"Jastreboff","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0039","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103423_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0043","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0044","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/HCO.0000000000001113","article-title":"Obesity\/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials","volume":"39","author":"Verma","year":"2024","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103423_bib0046","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626001659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626001659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:25:07Z","timestamp":1788787507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0146280626001659"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103423","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103423"}}